Critical Contrast: NKGen Biotech (NKGN) and The Competition

NKGen Biotech (NYSE:NKGN) is one of 283 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare NKGen Biotech to similar companies based on the strength of its analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Profitability

This table compares NKGen Biotech and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
NKGen Biotech Competitors	-5,121.43%	-172.90%	-43.61%

Valuation & Earnings

This table compares NKGen Biotech and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NKGen Biotech	$80,000.00	-$82.94 million	-0.08
NKGen Biotech Competitors	$566.95 million	-$34.50 million	-42.22

NKGen Biotech’s competitors have higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations for NKGen Biotech and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0	0	0	0	N/A
NKGen Biotech Competitors	1605	4796	12428	243	2.59

As a group, “Biological products, except diagnostic” companies have a potential upside of 67.14%. Given NKGen Biotech’s competitors higher probable upside, analysts clearly believe NKGen Biotech has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 20.0% of NKGen Biotech shares are owned by company insiders. Comparatively, 16.1% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

NKGen Biotech has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, NKGen Biotech’s competitors have a beta of 1.08, meaning that their average share price is 8% more volatile than the S&P 500.

NKGen Biotech Company Profile

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.